Juno Therapeutics, Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[1] The company raised $300 million through private funding and a further $265 million through their IPO.
On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.[2]
In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.[3]
History
In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.